Key result
Updated 2023 guidelines for infective endocarditis in adult congenital heart disease incorporate PET/CT imaging and new microbiological tests for diagnosis, and no longer recommend clindamycin for prophylaxis.
Why the study?
Care for infective endocarditis in adult patients with congenital heart disease is evolving with updated diagnostic criteria, new imaging and microbiological tools, and changing prevention guidelines.
This review provides an updated overview of infective endocarditis in adult congenital heart disease, emphasizing new diagnostic modalities like PET/CT and changes in antibiotic prophylaxis guidelines.
Supports endocarditis teams and 2023 criteria in ACHD IE care; leaves open prospective validation of outcomes.
PURPOSE OF REVIEW: Present an updated overview of the prevention, diagnosis, and management of infective endocarditis in adult patients with congenital heart disease. RECENT FINDINGS: Care for patients with infective endocarditis is changing in the areas of specialized teams, diagnostics, and prevention. Endocarditis teams should be involved in the care of ACHD patients. The 2023 Duke Criteria for Infective Endocarditis and the 2023 European Society of Cardiology Guidelines have updated the criteria for diagnosis including new major criteria such as CT and positron emission computed tomography with 18F-fluorodeoxyglucose (FDG) scans. Immunological, PCR, and nucleic acid-based tests are now acceptable means to isolate infective organisms. Clindamycin is no longer recommended for antibiotic prophylaxis due to resistance and side effect profile. Special considerations for antibiotic prophylaxis and management must be made for specific congenital heart diseases in adulthood and pregnant ACHD patients. Infective endocarditis (IE), a potentially devastating clinical entity, is a feared threat to the health of adults with congenital heart disease (ACHD). IE needs a systematic approach for its prevention, early diagnosis and management with a multidisciplinary IE team's involvement. There have been changes in the diagnostics and management of IE, which is reflected in updated diagnostic criteria. Timely blood cultures and imaging continue to be the mainstay of diagnosis, however the timing of blood cultures, microbiological testing, and types of diagnostic imaging such as the positron emission computed tomography with 18F-fluorodeoxyglucose (FDG) scan are new. Bicuspid aortic valves, ventricular septal defects, transcatheter pulmonary valve replacements, and tetralogy of Fallot are diagnoses at higher risk for IE in the ACHD population. The following article will focus on the preventive strategies, in addition to novel diagnostic and therapeutic approaches of IE in ACHD patients.
No takes yet. Share an insight, caveat, or question.
Carvajal et al. (2024) conducted a review in Infective endocarditis in adult congenital heart disease. Updated diagnostic criteria and management strategies was evaluated. Updated 2023 guidelines for infective endocarditis in adult congenital heart disease incorporate PET/CT imaging and new microbiological tests for diagnosis, and no longer recommend clindamycin for prophylaxis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: